3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine. (September 2015) - Queirolo, P.; Spagnolo, F.; Picasso, V.; Simeone, E.; Grimaldi, A.M.; Curvietto, M.; Giorello, L.; Fontana, V.; Merlo, D.F.; Ascierto, P.A.; Bruzzi, P.